Mostrar el registro sencillo del ítem

dc.contributor.author
Lynch, Joseph P.  
dc.contributor.author
Fishbein, Michael  
dc.contributor.author
Echavarría, Marcela Silvia  
dc.date.available
2023-04-13T12:47:30Z  
dc.date.issued
2011-08  
dc.identifier.citation
Lynch, Joseph P.; Fishbein, Michael; Echavarría, Marcela Silvia; Adenovirus; Thieme Medical Publ Inc; Seminars In Respiratory And Critical Care Medicine; 32; 4; 8-2011; 494-511  
dc.identifier.issn
1069-3424  
dc.identifier.uri
http://hdl.handle.net/11336/193656  
dc.description.abstract
Adenoviruses (AdV) are DNA viruses that typically cause mild infections involving the upper or lower respiratory tract, gastrointestinal (GI) tract, or conjunctiva. Rare manifestations of AdV infections include hemorrhagic cystitis, hepatitis, hemorrhagic colitis, pancreatitis, nephritis, or encephalitis. Adenovirus infections are more common in young children, owing to lack of humoral immunity. Epidemics of AdV infections may occur in healthy children or adults in closed or crowded settings (particularly military recruits). The disease is more severe, and dissemination is more likely in patients with impaired immunity (eg, organ transplant recipients, human immunodeficiency virus infection, congenital immunodeficiency syndromes). Fatality rates for untreated severe AdV pneumonia or disseminated disease may exceed 50%. More than 50 serotypes of AdV have been identified. Different serotypes display different tissue trophisms and correlate with clinical manifestations of infection. The predominant serotypes differ among countries or regions and change over time. Transmission of novel strains between countries or across continents and replacement of dominant serotypes by new strains may occur. Treatment of AdV infections is controversial because prospective, randomized therapeutic trials have not been done. Cidofovir is considered the drug of choice for severe AdV infections, but not all patients require treatment. Vaccines have been shown to be highly efficacious in reducing the risk of respiratory AdV infection but are currently not available.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Thieme Medical Publ Inc  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
ADENOVIRUS  
dc.subject
CIDOFOVIR  
dc.subject
RESPIRATORY VIRAL INFECTION  
dc.subject
SEROTYPES  
dc.subject.classification
Enfermedades Infecciosas  
dc.subject.classification
Ciencias de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Adenovirus  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2023-04-05T15:25:58Z  
dc.journal.volume
32  
dc.journal.number
4  
dc.journal.pagination
494-511  
dc.journal.pais
Estados Unidos  
dc.description.fil
Fil: Lynch, Joseph P.. University of California at Los Angeles. School of Medicine; Estados Unidos  
dc.description.fil
Fil: Fishbein, Michael. University of California at Los Angeles. School of Medicine; Estados Unidos  
dc.description.fil
Fil: Echavarría, Marcela Silvia. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.journal.title
Seminars In Respiratory And Critical Care Medicine  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0031-1283287  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1055/s-0031-1283287